Mindaugas Galvosas, MD
@mgalvosas.bsky.social did:plc:obfvh5sbhlapv2nooimkthu3
Neuroscience Digital Biomarkers @ indivi.io | prev. cough as a digital biomarker @ hyfe.com; founder of wandering prevention tech for dementia | interested in Digital Health | my opinions
En Bluesky desde el
- Seguidores
- 4.072
- Siguiendo
- 2.253
- Posts
- 991
- Días en rankings
- 0
Resumen
Mindaugas Galvosas, MD (@mgalvosas.bsky.social) es un usuario de Bluesky que se unió el 7 febrero 2024. Tiene 4.072 seguidores, sigue a 2.253 cuentas y ha publicado 991 posts.
Apariciones en rankings
Los mejores días en que los posts de esta cuenta entraron en la lista diaria de Debya.
Esta cuenta aún no ha aparecido en un ranking diario.
Posts que le gustaron recientemente
Me gusta públicos de la red Bluesky.
Giving up on deep space tonight with such a bright, but beautiful moon! #astrophotography
Ver postIf you haven’t read it yet👇 Sample Size and Power Calculations Based on Endpoint Responsiveness: Applications to Trials of Disease-Modifying Therapies in Parkinson’s Disease www.medrxiv.org/content/10.6...
Ver postIt was a really successful International Parkinson and Movement Disorder Society congress in Seoul this year for Indivi #MDSCongress #MDS2026
Ver postDo all DM1 therapies need to be oligonucleotides? What about: -> small molecules? -> engineered RNA-binding proteins? -> gene and repeat targeting? -> drug repurposing? Future DM1 therapies discussed at #WMS2026 will extend beyond oligonucleotides alone
Ver postIn his #WMS2026 talk "Advances in Translational Therapeutics for DM1," Prof. Masayuki Nakamori (Yamaguchi University) highlighted how quickly the DM1 pipeline has matured, and also what remains to be solved: the endpoint
Ver post
Cuentas que bloquea
En Bluesky los bloqueos son registros públicos.
